Bolus infusions of cangrelor 20 mg resulted in sufficient platelet inhibition for 20 min in 90% of healthy volunteers, and continuous infusion maintained this effect.
Does cangrelor administered via bolus and continuous infusion using an IV flow regulator provide sufficient platelet inhibition in healthy volunteers?
Weight-adapted bolus followed by continuous infusion of cangrelor via an IV flow regulator provides immediate and sustained platelet inhibition, suggesting a feasible prehospital strategy for acute STEMI management.
BACKGROUND: High on-treatment platelet reactivity (HTPR) remains a major problem in the acute management of ST-elevation myocardial infarction (STEMI), leading to higher rates of stent thrombosis and mortality. We aimed to investigate a novel, prehospital treatment strategy using cangrelor and tested its pharmacodynamic effects in a model using healthy volunteers. METHODS: We conducted a dose-finding, open-label, pilot trial including 12 healthy volunteers and tested three ascending bolus infusions of cangrelor (5 mg, 10 mg and 20 mg) and a bolus infusion followed by a continuous infusion via an intravenous (IV) flow regulator. Platelet function was assessed using multiple electrode aggregometry (MEA), vasodilator-stimulated phosphoprotein phosphorylation assay (VASP-P) and the platelet function analyzer. In an ex vivo experiment, epinephrine was used to counteract the antiplatelet effect of cangrelor. RESULTS: All cangrelor bolus infusions resulted in immediate and pronounced platelet inhibition. Bolus infusions of cangrelor 20 mg resulted in sufficient platelet inhibition assessed by MEA for 20 min in 90% of subjects. Infusion of cangrelor via the IV flow regulator resulted in sufficient platelet inhibition throughout the course of administration. Ex vivo epinephrine, in concentrations of 200 and 500 ng/mL was able to partially reverse the antiplatelet effect of cangrelor in a dose-dependent manner. CONCLUSIONS: Weight-adapted bolus infusions followed by a continuous infusion of cangrelor via IV flow regulator result in immediate and pronounced platelet inhibition in healthy subjects. Cangrelor given as weight-adapted bolus infusion followed by a continuous infusion using an IV flow regulator may be a viable treatment approach for effective and well controllable prehospital platelet inhibition. TRIAL REGISTRATION: EC (Medical University of Vienna) 1835/2019 and EudraCT 2019-002792-34 .
Gelbenegger et al. (Thu,) conducted a other in Healthy volunteers (n=12). Cangrelor was evaluated on Platelet inhibition assessed by multiple electrode aggregometry. Bolus infusions of cangrelor 20 mg resulted in sufficient platelet inhibition for 20 min in 90% of healthy volunteers, and continuous infusion maintained this effect.